IDEXX Laboratories (IDXX) insider files Form 144 to sell 5,371 shares

Rhea-AI Filing Summary

IDEXX Laboratories (IDXX) filed a Form 144 notice for a planned sale of 5,371 shares of common stock. The shares are expected to be sold through Morgan Stanley Smith Barney LLC on or around 02/17/2026, with an indicated aggregate market value of $3,369,666.57.

The securities were acquired on 02/17/2026 via a stock option exercise from the issuer, paid in cash on the same date. The filing notes that 79,851,330 shares of common stock were outstanding, providing a baseline context for the size of this planned sale.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5371	3369666.57	79851330	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/17/2026	Stock Option Exercise	Issuer			5371	02/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for IDXX disclose?

The Form 144 for IDXX discloses a planned sale of 5,371 common shares under Rule 144. The shares were recently acquired through a stock option exercise and are to be sold through Morgan Stanley at an indicated value of $3,369,666.57.

How many IDEXX Laboratories (IDXX) shares are planned to be sold?

The filing shows a planned sale of 5,371 IDXX common shares. These shares were acquired on 02/17/2026 via a stock option exercise and are scheduled for sale on or about the same date through Morgan Stanley Smith Barney LLC.

What is the aggregate market value of IDXX shares in this Form 144?

The planned sale of 5,371 IDXX shares has an indicated aggregate market value of $3,369,666.57. This value reflects the filer’s estimate for the Rule 144 transaction to be executed through Morgan Stanley Smith Barney LLC on or about 02/17/2026.

How were the IDXX shares in the Form 144 acquired?

The 5,371 IDXX common shares were acquired via a stock option exercise from the issuer on 02/17/2026. The Form 144 states that the exercise was paid in cash on the same date, immediately preceding the planned resale under Rule 144.

What does the Form 144 say about IDXX shares outstanding?

The notice states that 79,851,330 IDXX common shares were outstanding. This provides context for the relative size of the planned 5,371-share sale under Rule 144, which is a small fraction of the total outstanding share count reported in the filing.

Which broker is handling the IDXX Rule 144 sale?

The Form 144 lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker for the sale. The broker’s office is identified at 1 New York Plaza, 8th Floor, New York, NY 10004, and the shares are to be sold on the NASDAQ market.